Akero Therapeutics, Inc. Gains 136.76%

Akero Therapeutics, Inc. (AKRO:NASDAQ) rocketted at $29.05, representing a gain of 136.8%. On Tue, Sep 13, 2022, AKRO:NASDAQ touched a New 2-Week High of $29.05. The stock appeared on our News Catalysts scanner on Tue, Sep 13, 2022 at 04:59 PM in the 'PUBLIC OFFERING' category. From Tue, Aug 30, 2022, the stock recorded 66.67% Up Days and 60.00% Green Days

About Akero Therapeutics, Inc. (AKRO:NASDAQ)

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical need. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate AKR-001 is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.